Key Points

  • Salesforce shares jumped 22%, marking the company's second-best trading day on record after quarterly earnings exceeded Wall Street expectations.
  • An expanded partnership with Anthropic and a $2.6 billion investment gain helped strengthen investor confidence in Salesforce's position in the rapidly evolving AI market.
  • The sharp rally spread across the software sector, easing some concerns that generative AI could fundamentally undermine the traditional software-as-a-service business model.
hero

Salesforce Delivers a Major Earnings Surprise

Salesforce shares surged 22% Thursday after the software giant reported stronger-than-expected second-quarter results, delivering one of the most significant single-day gains in its history. The move was Salesforce’s second-best trading session ever, surpassed only by a roughly 26% advance in August 2020.

Revenue reached $11.35 billion, slightly above the $11.32 billion expected by LSEG analysts and representing 11% year-over-year growth. The earnings performance was considerably stronger, with adjusted earnings of $5.90 per share compared with the $3.27 consensus estimate.

Net income also increased sharply, rising 87% year over year to $3.53 billion, or $4.29 per share, from $1.89 billion, or $1.96 per share, in the comparable period. The combination of double-digit revenue growth and substantially higher profitability gave investors evidence that Salesforce remains capable of expanding earnings even as the software industry undergoes significant technological change.

Anthropic Partnership Changes the AI Narrative

The earnings beat was accompanied by a major expansion of Salesforce’s relationship with Anthropic. Salesforce CEO Marc Benioff and Anthropic CEO Dario Amodei introduced “Claudeforce,” an initiative designed to bring Anthropic’s Claude technology into Salesforce workflows. The integration is intended to allow sales professionals to access important business data through Claude, strengthening the connection between enterprise software and increasingly capable AI models.

The partnership is significant because investors have spent much of the year questioning whether generative AI could eventually weaken the traditional SaaS model. Salesforce has pushed back against that concern, arguing that AI can instead increase the value of enterprise software by making business data more accessible and workflows more automated.

Salesforce also disclosed a $2.6 billion gain from its strategic investment in Anthropic. With Anthropic’s valuation having risen sharply, the investment provides Salesforce with an additional financial benefit from the AI boom while reinforcing its strategic relationship with one of the industry’s leading model developers.

Software Sector Rebounds on Reduced SaaS Fears

The reaction extended well beyond Salesforce. Shares of Adobe, Palantir, ServiceNow, Autodesk and Figma all advanced, while the iShares Expanded Tech-Software ETF gained roughly 5%. The broad move suggests that investors interpreted Salesforce’s results as evidence that AI may complement established software platforms rather than simply replace them.

That distinction is increasingly important for the sector. Software stocks have faced pressure as investors considered whether AI models could perform tasks traditionally handled by specialized applications, potentially reducing demand for conventional SaaS products. Salesforce’s results offered a more constructive scenario in which enterprise software remains the infrastructure through which businesses organize data, workflows and AI-enabled services.

Going forward, investors will be watching whether Salesforce can convert its AI partnerships into sustained customer adoption and recurring revenue growth. The immediate rally has materially changed market sentiment, but the longer-term test will be whether AI becomes an incremental growth engine rather than simply a catalyst for valuation expansion. Results from other major software companies will provide further evidence of whether the sector’s AI-driven recovery can broaden beyond Salesforce.

 


Comparison, examination, and analysis between investment houses

Leave your details, and an expert from our team will get back to you as soon as possible

    * This article, in whole or in part, does not contain any promise of investment returns, nor does it constitute professional advice to make investments in any particular field.

    To read more about the full disclaimer, click here
    SKN | Could Delta’s Higher Fares Offset Rising Fuel Costs as the Airline Cuts Its 2026 Profit Forecast?
    • omer bar
    • •
    • 8 Min Read
    • •
    • ago 8 hours

    SKN | Could Delta’s Higher Fares Offset Rising Fuel Costs as the Airline Cuts Its 2026 Profit Forecast? SKN | Could Delta’s Higher Fares Offset Rising Fuel Costs as the Airline Cuts Its 2026 Profit Forecast?

    Delta Air Lines has lowered its 2026 profit expectations as soaring jet fuel costs weigh on earnings, highlighting the challenge

    • ago 8 hours
    • •
    • 8 Min Read

    Delta Air Lines has lowered its 2026 profit expectations as soaring jet fuel costs weigh on earnings, highlighting the challenge

    SKN | Could Samsung’s Record Profit Signal Another Major Phase of the AI Chip Boom?
    • Ronny Mor
    • •
    • 6 Min Read
    • •
    • ago 2 days

    SKN | Could Samsung’s Record Profit Signal Another Major Phase of the AI Chip Boom? SKN | Could Samsung’s Record Profit Signal Another Major Phase of the AI Chip Boom?

    Samsung Electronics is projecting its strongest quarterly profitability on record, underscoring the extraordinary impact that the artificial intelligence boom is

    • ago 2 days
    • •
    • 6 Min Read

    Samsung Electronics is projecting its strongest quarterly profitability on record, underscoring the extraordinary impact that the artificial intelligence boom is

    SKN | Could Summit’s Ivonescimab Help AstraZeneca Build the Next Generation of Cancer Treatments?
    • Ronny Mor
    • •
    • 7 Min Read
    • •
    • ago 4 days

    SKN | Could Summit’s Ivonescimab Help AstraZeneca Build the Next Generation of Cancer Treatments? SKN | Could Summit’s Ivonescimab Help AstraZeneca Build the Next Generation of Cancer Treatments?

    Summit Deal Puts Ivonescimab at the Center of AstraZeneca’s Strategy AstraZeneca is positioning its investment in Summit Therapeutics around the

    • ago 4 days
    • •
    • 7 Min Read

    Summit Deal Puts Ivonescimab at the Center of AstraZeneca’s Strategy AstraZeneca is positioning its investment in Summit Therapeutics around the

    SKN | Could Boeing’s New Fighter Jet Wins Mark a Turning Point for Its Defense Business?
    • Lior mor
    • •
    • 8 Min Read
    • •
    • ago 4 days

    SKN | Could Boeing’s New Fighter Jet Wins Mark a Turning Point for Its Defense Business? SKN | Could Boeing’s New Fighter Jet Wins Mark a Turning Point for Its Defense Business?

    Boeing Expands Its Position in Next-Generation Fighters Boeing has strengthened its position in the U.S. military aircraft market after securing

    • ago 4 days
    • •
    • 8 Min Read

    Boeing Expands Its Position in Next-Generation Fighters Boeing has strengthened its position in the U.S. military aircraft market after securing